Arch Fam Med
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 1 No. 2, November 1992 TABLE OF CONTENTS
  •  Online Features
  Clinical Reviews
 This Article
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Metoclopramide-Associated Tardive Dyskinesia

An Analysis of 67 Cases

Daniel D. Sewell, MD; Dilip V. Jeste, MD

Arch Fam Med. 1992;1(2):271-278.

Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

1. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1980:23.
2. Perry PJ, Alexander B, Liskow Bl. Psychotropic Drug Handbook. 5th ed. Cincinnati, Ohio: Harvey Whitney Books; 1988:28.
3. Jeste DV, Yassa R. Neuroleptic-induced tardive dyskinesia. In: Francis A, ed. DSM-IV Sourcebook. Washington, DC: American Psychiatric Association. In press.
4. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481. FREE FULL TEXT
5. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press; 1982.
6. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacologic treatment of tardive dyskinesia in the 1980s. J Clin Psychopharmacol. 1988;8(suppl):38-48. PUBMED
7. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-394. FREE FULL TEXT
8. Tancredi LR. Malpractice and tardive dyskinesia: a conceptual dilemma. J Clin Psychopharmacol. 1988;8(suppl):71-76. PUBMED
9. Casteels-Van Daele M, Jaelen J, Van Der Schueren P, Zimmerman A, Van Den Bon P. Dystonic reactions in children caused by metoclopramide. Arch Dis Child. 1970;45:130-133. FREE FULL TEXT
10. Robinson OPW. Metoclopramide: side effects and safety. Postgrad Med J. 1973;49(suppl):77-80. FREE FULL TEXT
11. Board AW. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med. 1986;315:518-519. PUBMED
12. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277-93-96. PUBMED
13. Alander T, Anden N, Grabowska-Anden M. Metoclopramide and sulpiride as selecting blocking agents of pre- and postsynaptic dopamine receptors. Naunyn Schmiedebergs Arch Phamacol. 1980;312:145-150.
14. Harrington RA, Hamilton CW, Brogden RN, Linkewich RA, Romankiewicz, Heel RC. Metoclopramide: an updated review of its pharmacologic properties and clinical use. Drug Eval. 1983;25:451-494.
15. Schutz E. Fortechritte in der Therapie des Ulcus duodeni. Munch Med Wochenschr. 1976;118:231-234.
16. Borenstein PP, Bles G. Effets cliniques et electroencephalographiques du metoclopramide en psychiatrie. Therapie. 1965;20:975-995. PUBMED
17. Nakra BRS, Bond AJ, Lader MH. Comparative psychotropic effects of metoclopramide and prochlorpromazine in normal subjects. J Clin Pharmacol. 1975;15:449-454. PUBMED
18. Stanley M, Wilk S. Striatal DOPAC elevation predicts antipsychotic efficacy of metoclopramide. Life Sci. 1979;24:1907-1912. PUBMED
19. Stanley M, Lautin A, Rotrosen J, Gershon S. Antipsychotic efficacy of metoclopramide: do DA/neuroleptic receptors mediate the action of antipsychotic drugs? IRCS Med Sci Clin Med Clin Pharmacol Nervous Sys Psychol Psychiatry. 1979;7:332.
20. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D. Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology. 1980;71:219-225. PUBMED
21. Borda IT. Drug treatment of gastrointestinal disorders. In: Swift CG, ed. Clinical Pharmacology in the Elderly. New York, NY: Marcel Dekker Inc; 1987:529-579.
22. Craig JB, Powell BL, White DR, Capizzi RL. Antiemetic therapy in patients treated with high-dose cytosine. Oncology. 1987;44:90-92. PUBMED
23. Physicians' Desk Reference, 45th Edition. Oradell, NJ: Medical Economics Books; 1991.
24. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ. 1985;291:930-932. FREE FULL TEXT
25. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:488-489. FREE FULL TEXT
26. Beauclair L, Fontaine R. Tardive dyskinesia associated with metoclopramide. Can Med Assoc J. 1986;134:613-614. PUBMED
27. Melmed S, Bank H. Metoclopramide and facial dyskinesia. BMJ. 1975;8:331.
28. Indo T, Ando K. Metoclopramide-induced parkinsonism: clinical characteristics of ten cases. Arch Neurol. 1982;39:494-496. FREE FULL TEXT
29. Leopold NA. Prolonged metoclopramide-induced dyskinetic reaction. Neurology. 1984;34:238-239. FREE FULL TEXT
30. Jankovic J, Glass JP. Metoclopramide-induced phantom dyskinesia. Neurology. 1985;35:432-435. FREE FULL TEXT
31. Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525-532. PUBMED
32. Grimes JD, Hassan MN, Krelina M. Long-term follow-up of tardive dyskinesia due to metoclopramide. Lancet. 1982;2:563. PUBMED
33. Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med. 1989;149:2486-2492. FREE FULL TEXT
34. Patel M, Louis S. Long-term neurologic complications of metoclopramide. N Y State J Med. 1986;86:210. PUBMED
35. Yamamoto M, Ujike H, Ogawa N. Metoclopramide-induced parkinsonism. Clin Neuropharmacol. 1987;10:287-289. PUBMED
36. Sewell DD, Yoshinobu BH, Caligiuri MP, Jeste DV. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus: two case reports. Gen Hosp Psychiatry. In press.
37. Wiholm BE, Mortimer 0, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. BMJ. 1984;288:545-547. FREE FULL TEXT
38. Ganzini L, Casey DE, Hoffman WF, Heintz RT. Tardive dyskinesia in neuroleptic-treated diabetics. Presented at the 30th Annual Meeting of the American College of Neuropsychopharmacology; December 10, 1991; San Juan, Puerto Rico.
39. Casey DE. Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE, eds. Tardive Dyskinesia and Affective Disorders. Washington, DC: American Psychiatric Association; 1984:1-20.
40. Shearer RM, Bownes IT, Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Ada Psychiatr Scand. 1984;70:428-431.
41. Breitbart W. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med. 1986;315:518. PUBMED
42. Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord. 1987;2:125-129. PUBMED
43. Kataria M, Traub M, Marsden CD. Extrapyramidal side-effects of metoclopramide. Lancet. 1978;2:1254-1255. PUBMED
44. Lang AE. Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesia. Can J Neurol Sci. 1990;17:137-139. PUBMED
45. Sirota RA, Kimmel PL, Trichtinger MA, Diamond BF, Stein HD, Yudis M. Metoclopramide-induced parkinsonism in hemodialysis patients: report of two cases. Arch Intern Med. 1986;146:2070-2071. FREE FULL TEXT
46. Casey DE, Hansen TE. Spontaneous dyskinesias. In: Jeste DV, Wyatt RJ, eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Association; 1984:67-95.
47. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1411-1419.
48. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry. 1981;138:297-309. FREE FULL TEXT
49. Lavy S, Melamed E, Penchas S. Tardive dyskinesia associated with metoclopramide. BMJ. 1978;1:77-78. FREE FULL TEXT
50. Lazzara RR, Stoudemire A, Manning D, Prewitt KC. Metoclopramide-induced tardive dyskinesia: a case report. Gen Hosp Psychiatry. 1986;8:107-109. PUBMED
51. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126:23-25. ABSTRACT
52. Casey DE. Metoclopramide side effects. Ann Intern Med. 1983;98:673-674. PUBMED
53. Kane JM, Woerner M, Lieberman J, Kinon B. Tardive dyskinesia. In: Jeste DV, Wyatt RJ, eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Association; 1984:97-118.
54. Hoffman WF, Labe SM, Casey DE. Neurolepticinduced parkinsonism in older schizophrenics. Biol Psychiatry. 1987;22:427-439. PUBMED
55. Gardos G, Perenyi A, Cole JO, Samu I, Kocsis E, Casey DE. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology. 1988;1:169-172. PUBMED
56. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol. 1972;27:426-430. FREE FULL TEXT
57. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharm. 1988;8(suppl):52-56.
58. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptictreated diabetics: a controlled study. Arch Gen Psychiatry. 1991;48:259-263. FREE FULL TEXT